Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence
Journal of Clinical Medicine · 28.03.2024 · 13 (7) · 1970
DOI: 10.3390/jcm13071970 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.03.2024. Verfasst von Ibrahim O Sawaid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ginsberg Foundation, Katz foundation.
Abstract (Originalsprache)
Background
Proton pump inhibitors (PPIs) are commonly prescribed long-acting drugs used to treat acid reflux, gastroesophageal reflux disease (GERD), and peptic ulcers. Recently, concerns have been raised about their safety, particularly due to the association between long-term PPI use and cancer development. Multiple comprehensive studies have consistently suggested a noteworthy link between prolonged PPI usage and an increased risk of developing gastric, esophageal, colorectal, and pancreatic cancers, yet the precise underlying mechanism remains elusive.
Methods
First, we review the extensive body of research that investigates the intricate relationship between cancer and PPIs. Then, we predict PPI toxicity using the prodrug structures with the ProTox-II webserver. Finally, we predict the relative risk of cancer for each PPI, using PubMed citation counts of each drug and keywords related to cancer.
Results
Our review indicates that prolonged PPI use (exceeding three months) is significantly associated with an elevated risk of cancer, while shorter-term usage (less than three months) appears to pose a comparatively lower risk. Our review encompasses various proposed mechanisms, such as pH and microbiome alterations, vitamin and mineral malabsorption, hypergastrinemia, and enterochromaffin-like cell proliferation, while ProTox-II also suggests aryl hydrocarbon receptor binding. Potentially, the PubMed citations count suggests that the PPIs omeprazole and lansoprazole are more associated with cancer than pantoprazole and esomeprazole. In comparison, the H2R blocker, famotidine, is potentially less associated with cancer than PPIs, and may serve as a safer alternative treatment for periods beyond 3 months.
Conclusions
Despite the well-established cancer risk associated with PPIs, it is notable that these medications continue to be widely prescribed for periods longer than 3 months. Thus, it is of paramount importance for clinicians and patients to thoughtfully evaluate the potential risks and benefits of long-term PPI usage and explore alternative treatments before making informed decisions regarding their medical management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Azrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
ORCID-Profile: Abraham O Samson
Förderung
- Ginsberg Foundation
- Katz foundation
Zitieren
APA
Sawaid, I. O., & Samson, A. O. (2024). Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. Journal of Clinical Medicine, 13(7), 1970. https://doi.org/10.3390/jcm13071970
Vancouver
Sawaid IO, Samson AO. Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence. Journal of Clinical Medicine. 2024;13(7):1970. doi:10.3390/jcm13071970
BibTeX
@article{Sawaid2024,
author = {Sawaid, Ibrahim O and Samson, Abraham O},
title = {Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {7},
pages = {1970},
doi = {10.3390/jcm13071970}
}
EUVIMED